Genentech, Inc.'s Avastin Disappoints Company Earnings

LOS ANGELES (Reuters) - Biotechnology company Genentech Inc (DNA.N: Quote, Profile, Research) said on Monday its fourth-quarter profit rose 6.4 percent, but sales of several drugs, including blockbuster cancer drug Avastin, fell short of investor expectations, sending the company's shares lower.

Back to news